Cambium Medical Technologies LLC signed a non-binding indicative offer letter to acquire Regeneus Ltd (ASX:RGS) for AUD 3.98 million in a reverse merger transaction on April 28, 2023. Under the terms, Regeneus will issue 306.4 million shares as consideration constituting more than 50% stake. The merged company will change its name to Cambium Bio Limited.

Completion is subject to approval of shareholders of Regeneus and Cambium and binding merger documentation. As on February 14, 2024, Cambium Medical Technologies LLC signed a binding merger agreement to acquire Regeneus Ltd (ASX:RGS). The transaction is expected to complete in March 2024.